New hope for women with aggressive ovarian cancer: testing a powerful drug duo
NCT ID NCT07314619
Summary
This study is testing a new two-drug combination for women whose ovarian cancer has returned and stopped responding to standard platinum-based chemotherapy. It will enroll about 30 participants to see if combining an antibody-drug conjugate (sacituzumab tirumotecan) with an existing drug (bevacizumab) is safe and more effective than current options. The goal is to better control the cancer's growth and extend survival for this difficult-to-treat condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450000, China
Conditions
Explore the condition pages connected to this study.